BI Asset Management Fondsmaeglerselskab A S Grows Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

BI Asset Management Fondsmaeglerselskab A S boosted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYFree Report) by 122.6% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 3,769 shares of the biopharmaceutical company’s stock after acquiring an additional 2,076 shares during the period. BI Asset Management Fondsmaeglerselskab A S’s holdings in Alnylam Pharmaceuticals were worth $721,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Quent Capital LLC grew its stake in shares of Alnylam Pharmaceuticals by 246.0% in the fourth quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 123 shares during the period. Anchor Investment Management LLC purchased a new stake in Alnylam Pharmaceuticals in the fourth quarter worth approximately $38,000. Robeco Institutional Asset Management B.V. boosted its position in Alnylam Pharmaceuticals by 155.7% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 12,513 shares during the last quarter. GAMMA Investing LLC bought a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at about $52,000. Finally, Lindbrook Capital LLC increased its position in shares of Alnylam Pharmaceuticals by 37.2% during the 4th quarter. Lindbrook Capital LLC now owns 369 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 100 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Needham & Company LLC reissued a “buy” rating and issued a $200.00 price objective on shares of Alnylam Pharmaceuticals in a report on Thursday, May 2nd. Citigroup cut their price objective on shares of Alnylam Pharmaceuticals from $237.00 to $227.00 and set a “buy” rating for the company in a research report on Friday, February 16th. Morgan Stanley decreased their target price on Alnylam Pharmaceuticals from $184.00 to $176.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 13th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $165.00 price objective on shares of Alnylam Pharmaceuticals in a report on Tuesday, February 20th. Finally, William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Monday, April 8th. Seven research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $216.19.

Get Our Latest Stock Report on ALNY

Alnylam Pharmaceuticals Trading Up 0.9 %

Shares of NASDAQ:ALNY opened at $150.90 on Thursday. The company has a market cap of $19.09 billion, a price-to-earnings ratio of -56.31 and a beta of 0.41. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $218.88. The company has a 50-day moving average price of $149.38 and a 200 day moving average price of $164.35.

Alnylam Pharmaceuticals (NASDAQ:ALNYGet Free Report) last issued its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.23. The company had revenue of $494.33 million for the quarter, compared to analysts’ expectations of $428.01 million. The company’s revenue for the quarter was up 54.8% on a year-over-year basis. During the same quarter last year, the company earned ($1.40) earnings per share. As a group, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -3.77 EPS for the current year.

Alnylam Pharmaceuticals Profile

(Free Report)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Further Reading

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYFree Report).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.